Skip to main content
. 2023 Jul 22;26(9):107455. doi: 10.1016/j.isci.2023.107455

Figure 6.

Figure 6

Pharmacological ADRB inhibition protected type H vessels and bone mass in estrogen deficiency

(A) CD31 (green) and EMCN (red) co-immunostaining, counterstained by DAPI (blue), at metaphysis of sham-operated mice, estrogen-deficient OVX mice and PRO-treated estrogen-deficient OVX mice after daily intraperitoneal injections of PRO for four weeks. Dashed lines indicate the margin of growth plates. Scale bar, 100 μm.

(B) Quantification of type H vessels density (%). N = 3 per group.

(C) Micro-CT analysis and 3D views of femurs of sham-operated mice, OVX mice and PRO-treated OVX mice. Scale bar of the lengthwise section, 500 μm. Scale bar of cross section and 3D views, 250 μm.

(D–G) Parameters analysis of trabecular bone mass. Tb.BV/TV, trabecular bone volume over tissue volume; Tb.Th, trabecular thickness; Tb.Sp, trabecular separation; Tb.N, trabecular number. N = 4 per group.

(H and I) Parameters analysis of cortical bone mass. Ct.Ar, cortical bone area; Ct.Th, cortical bone thickness. N = 4 per group.

Data represent mean ± SD. Statistical analysis is performed by Student’s t test for two-group comparison or by one-way analysis of variance followed by Newman–Keuls post-hoc tests for multiple comparisons. ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001.